Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KYMR Kymera Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: KYMR
Price (delayed)
$31.16
Market cap
$2.03B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.11
Enterprise value
$2.02B
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein
Highlights
KYMR's gross profit is down by 26% year-on-year but it is up by 25% since the previous quarter
KYMR's revenue is down by 26% YoY but it is up by 25% from the previous quarter
KYMR's net income has dropped by 56% year-on-year and by 8% since the previous quarter
The company's EPS fell by 24% YoY and by 4.4% QoQ
Key stats
What are the main financial stats of KYMR
Market
Valuations
Earnings
Shares outstanding
65.12M
Market cap
$2.03B
Enterprise value
$2.02B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.57
Price to sales (P/S)
42.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.3
Revenue
$58.89M
Gross profit
$58.89M
Operating income
-$278.23M
Net income
-$240.88M
EBIT
-$240.63M
EBITDA
-$232.67M
Free cash flow
-$239.96M
Per share
Balance sheet
Liquidity
EPS
-$3.11
EPS diluted
-$3.11
Free cash flow per share
-$2.99
Book value per share
$12.11
Revenue per share
$0.73
TBVPS
$11.46
Total assets
$918.31M
Total liabilities
$132.08M
Debt
$86.33M
Equity
$786.23M
Working capital
$441.96M
Debt to equity
0.11
Current ratio
8.49
Quick ratio
7.95
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
-395.1%
Gross margin
100%
Net margin
-409.1%
Operating margin
-472.5%
Return on assets
-25.6%
Return on equity
-30.1%
Return on invested capital
-28%
Return on capital employed
-28%
Return on sales
-408.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KYMR stock price
How has the Kymera Therapeutics stock price performed over time
Intraday
3.18%
1 week
0.06%
1 month
19.98%
1 year
-13.47%
YTD
-22.55%
QTD
13.85%
Financial performance
How have Kymera Therapeutics's revenue and profit performed over time
Revenue
$58.89M
Gross profit
$58.89M
Operating income
-$278.23M
Net income
-$240.88M
Gross margin
100%
Net margin
-409.1%
The operating margin has plunged by 111% YoY but it has grown by 15% from the previous quarter
KYMR's net margin has dropped by 110% year-on-year but it is up by 14% since the previous quarter
The company's operating income has shrunk by 56% YoY and by 6% QoQ
KYMR's net income has dropped by 56% year-on-year and by 8% since the previous quarter
Price vs fundamentals
How does KYMR's price correlate with its fundamentals
Growth
What is Kymera Therapeutics's growth rate over time
Valuation
What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
2.57
P/S
42.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.3
The company's EPS fell by 24% YoY and by 4.4% QoQ
The stock's price to book (P/B) is 42% less than its 5-year quarterly average of 4.3 and 11% less than its last 4 quarters average of 2.8
The equity has grown by 11% YoY but it has contracted by 6% from the previous quarter
KYMR's revenue is down by 26% YoY but it is up by 25% from the previous quarter
The price to sales (P/S) is 25% higher than the 5-year quarterly average of 32.8
Efficiency
How efficient is Kymera Therapeutics business performance
The company's return on sales has shrunk by 110% YoY but it rose by 14% QoQ
KYMR's return on assets is down by 7% year-on-year and by 6% since the previous quarter
The company's return on equity rose by 6% YoY but it fell by 4.9% QoQ
The return on invested capital has declined by 6% since the previous quarter and by 3.7% year-on-year
Dividends
What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KYMR.
Financial health
How did Kymera Therapeutics financials performed over time
The total liabilities has contracted by 16% YoY and by 7% from the previous quarter
Kymera Therapeutics's quick ratio has decreased by 15% YoY but it has increased by 9% QoQ
KYMR's debt is 89% smaller than its equity
The equity has grown by 11% YoY but it has contracted by 6% from the previous quarter
Kymera Therapeutics's debt to equity has decreased by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.